Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Brief: Abcellera Announces First Patients Dosed In Phase 2 Portion Of Its Phase 1/2 Clinical Trial Of Abcl635 For The Treatment Of Vasomotor Symptoms Due To Menopause

Jan 12 (Reuters) - Abcellera Biologics Inc ABCL.O:

ABCELLERA ANNOUNCES FIRST PATIENTS DOSED IN PHASE 2 PORTION OF ITS PHASE 1/2 CLINICAL TRIAL OF ABCL635 FOR THE TREATMENT OF VASOMOTOR SYMPTOMS DUE TO MENOPAUSE

ABCELLERA BIOLOGICS INC - ANTICIPATES TOP-LINE RESULTS IN Q3 2026

Source text: ID:nBw9Gjzr2a

Further company coverage: ABCL.O

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on AbCellera Biologics

See all news